Nancy J. Hutson - Jun 13, 2023 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role
Director
Signature
/s/ Alane P. Barnes, by power of attorney
Stock symbol
BCRX
Transactions as of
Jun 13, 2023
Transactions value $
-$103,443
Form type
4
Date filed
6/15/2023, 04:33 PM
Previous filing
May 19, 2023
Next filing
Jun 23, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCRX Common Stock Award $0 +16.7K +21.48% $0.00 94.7K Jun 13, 2023 Direct F1
transaction BCRX Common Stock Sale -$103K -12.9K -13.59% $8.04 81.8K Jun 14, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCRX Automatic Stock Option Grant Award $0 +39.1K $0.00 39.1K Jun 13, 2023 Common Stock 39.1K $8.18 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
F2 The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $7.89 to $8.12. The reporting person will provide to the issuer, or any security holder of the issuer, or the SEC staff upon request, full information regarding the number of shares purchased at each price within the range set forth in the footnote.
F3 Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.